[Edaily Reporter Hyera Lee ] #EGIS Co., Ltd announced on the 22nd that it has successfully implemented a solution that integrates NVIDIA Omniverse with its proprietary digital twin operating system (OS). EGIS Co., Ltd CI. (Photo courtesy of EGIS Co., Ltd) This solution is designed to transmit real-world data managed by the digital twin OS to NVIDIA Omniverse to perform high-precision 3D simulations and rendering, and then integrate the results back into the digital twin OS for unified operation. The company has implemented a system that converts data—such as terrain, buildings, facilities, and objects—managed by its proprietary digital twin OS into OpenUSD-based 3D simulation data for use in Omniverse. Based on this, the company plans to expand its scope of application to various industries, including AI manufacturing infrastructure, robots, drones, and energy infrastructure. Additionally, the company intends to pursue official registration as an Omniverse solution within the year and plans to further advance the technology by adding features such as real-time data conversion and Agent AI-based automated analysis in the future. EGIS Co., Ltd. stated, “The core of this solution lies in implementing digital twin 3D data processing technology within the NVIDIA Omniverse environment,” adding, “Now that we have established a foundation for validating physical AI manufacturing infrastructure, we plan to expand our services into various industries such as manufacturing, robotics, and drones.”
SK Eco Plant and KCC Corporation(002380)achieved a successful public offering of corporate bonds, drawing a favorable response in the bookbuilding process despite significant uncertainty caused by a s…
Tous Les Jours, a bakery brand operated by CJ Corp., is raising prices on some of its products. The company decided to adjust prices on certain items due to rising international prices for raw materia…
Jeon Seung-ho, Co-CEO of Kolon TissueGene, Inc. (Photo: ReporterKIM SAE-MI )
“Right up until two days before we learned of the TG-C Phase 3 clinical trial topline data, I was still meeting with co…